triple-negative breast cancer mRNA-based drug (BPgene )

N/A

Report date: 2025/01/26 17:25:57
NME

Base Information

Drug Nametriple-negative breast cancer mRNA-based drug (BPgene )
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBPgene Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBPgene Co Ltd
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A